Cabozantinib for patients with advanced hepatocellular carcinoma: a cost-effectiveness analysis.
Amir ShlomaiMoshe LeshnoDaniel A GoldsteinPublished in: Therapeutic advances in gastroenterology (2019)
Our results suggest that the use of cabozantinib in patients with advanced HCC who have progressed on prior treatment, results in a modest incremental benefit with high incremental costs, suggesting that it is not cost-effective at conventional willingness to pay thresholds.